- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merck (MRK)
Find here information about Merck (MRK) share price. You can find more details about NYSE: MRK by going to one of the sections listed on this page such as historical data, price charts, MRK share price technical analysis and more.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
110.97
112.89
52 wk Range
75.40
125.14
MRK is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
110.97112.89
52 wk Range
75.40125.14
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.02%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.02%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
129.74
Upside
+15.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 15 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
19 Buy
10 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 129.74
(+15.26% Upside)
Merck & Company Inc SWOT Analysis
Keytruda's Dominance | Explore Merck's reliance on cancer drug Keytruda, its impressive growth, and the looming patent cliff in 2028 that poses significant revenue challenges |
Gardasil Hurdles | Delve into Merck's strategic pause of Gardasil sales in China, impacting 2025 forecasts and raising concerns about inventory management and market dynamics |
Pipeline Potential | Learn about Merck's promising pipeline, including TROP2 ADC and KRAS inhibitors, as the company seeks to diversify beyond Keytruda and address future growth |
M&A Strategy | Analysts eye Merck's robust balance sheet and M&A potential, with acquisitions in the $1-15 billion range, as key to filling the post-Keytruda revenue gap |
Merck & Company Inc Earnings Call Summary for Q1/2026
- Merck Q1 2026 EPS of -$1.28 beat forecast of -$1.48; revenue hit $16.29B, up 5% YoY, exceeding estimates by 2.52%
- Stock fell 2.61% pre-market to $108.05 despite earnings beat, due to $3.62/share one-time charge from Sedera Therapeutics acquisition
- Oncology segment led by Keytruda drove growth; gross margin declined slightly to 81.9% amid $15.2B operating expenses from acquisition
- Full-year revenue guidance raised to $65.8B-$67B (1%-3% growth); EPS forecast $5.04-$5.16 with positive FX impact expected
- Key risks include Sedera integration costs, declining Gardasil sales in international markets, and regulatory challenges for new approvals
Last Updated: 30/04/2026, 16:10
Read Full TranscriptEarnings
Latest Release
30/04/2026
EPS / Forecast
-1.28 / -1.48
Revenue / Forecast
16.29B / 15.89B
Compare MRK to Peers and Sector
Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.1x | 20.1x | −0.5x | |
PEG Ratio | −0.65 | 0.36 | 0.00 | |
Price/Book | 6.1x | 1.4x | 2.6x | |
Price / LTM Sales | 4.2x | 1.9x | 3.2x | |
Upside (Analyst Target) | 19.9% | 0.0% | 55.3% | |
Fair Value Upside | Unlock | 33.1% | 9.7% | Unlock |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Merck&Co (NYSE: MRK) Share Price Today?
The Merck&Co stock price today is 112.56 USD.
What Stock Exchange Does Merck&Co (MRK) Trade On?
Merck&Co is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Merck&Co?
The stock symbol (also called a 'ticker') for Merck&Co is "MRK."
Does Merck&Co Pay Dividends? What’s The Current MRK Dividend Yield?
Yes, MRK Pays Dividends to its Shareholders. The current Merck&Co dividend yield is 3.02%.
What Is the Current Merck&Co Market Capitalisation?
As of today, Merck&Co (NYSE: MRK) market cap is 278.00B USD.
What Is Merck&Co's (MRK) Earnings Per Share (TTM)?
The Merck&Co EPS is currently 3.58 (Trailing Twelve Months).
When Is the Next Merck&Co Earnings Date?
Merck&Co's next earnings report will be released on 04/08/2026.
Is MRK a Buy or Sell From a Technical Analyst Perspective?
Based on today's Merck&Co moving averages and other technical indicators, the daily buy/sell signal for MRK stock is Neutral.
How Many Times Has Merck&Co Stock Split?
Merck&Co has split 5 times. (See the MRK stock split history page for full effective split date and price information.)
How Many Employees Does Merck&Co Have?
Merck&Co has 74000 employees, based on their latest Companies House report.
What is the current trading status of Merck&Co (NYSE: MRK)?
As of 19/05/2026, Merck&Co (MRK) is trading at a share price of 112.56 USD, with a previous close of 112.56 USD. The stock has fluctuated within a day range of 110.97 USD to 112.89 USD, while its 52-week range spans from 75.40 USD to 125.14 USD.
What Is Merck&Co (MRK) Price Target According to Analysts?
The average 12-month price target for Merck&Co is 129.74 USD, with a high estimate of 150 USD and a low estimate of 100 USD. 19 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +15.26% Upside potential.
What Is the MRK Premarket Price?
MRK's last pre-market stock price is 112.40 USD. The pre-market share volume is 1,020.00, and the stock has decreased by -0.16, or -0.14%.
What Is the MRK After Hours Price?
MRK's last after hours stock price is 112.60 USD, the stock has decreased by 0.04, or 0.04%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.